Disseminated intravascular coagulation following administration of sunitinib

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Sunitinib is an oral targeted therapy used for various cancers, including renal cell carcinoma and gastrointestinal stromal tumors.
• It functions by inhibiting tyrosine kinases like VEGFR and PDGFR.
• While generally well-tolerated, sunitinib can cause side effects, ranging from mild to severe.

Purpose of the Study:

• To report the first documented case of disseminated intravascular coagulation (DIC) associated with sunitinib treatment.
• To highlight a potential rare adverse event in patients undergoing sunitinib therapy.

Main Methods:

• Case report detailing a patient treated with sunitinib.
• Review of the patient's clinical presentation, laboratory findings, and treatment course.
• Correlation of adverse event onset with sunitinib dosage adjustments.

Main Results:

• The study presents the first reported case of disseminated intravascular coagulation (DIC) in a patient receiving sunitinib.
• This severe adverse event occurred shortly after an increase in the sunitinib dosage.
• Common side effects of sunitinib include fatigue and gastrointestinal issues, while severe events like hemorrhage are less frequent.

Conclusions:

• Disseminated intravascular coagulation (DIC) is a potential, albeit rare, adverse event associated with sunitinib therapy.
• Clinicians should be vigilant for signs of DIC in patients treated with sunitinib, especially following dosage changes.
• Further investigation may be warranted to understand the mechanism linking sunitinib to DIC.